Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Innate Immunotherapeutics Limited
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew John Sneddon
Date of last notice	12 September 2016

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	HSBC Custody Nominees (Australia) Limited as custodian for Andrew Sneddon & Judith Sneddon ATF Sneddon Family Superannuation Fund
Date of change	28 June 2017

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held prior to	Direct:
change	
change	Andrew Sneddon:  1,000,000 Options – Exercise Price A\$0.45 Expiry Date of 5 November 2018 600,000 Options – Exercise Price A\$0.65 Expiry Date of 31 August 2018  Andrew Sneddon <aj family="" sneddon="" trust="">: 364,893 Fully Paid Ordinary Shares  Andrew Sneddon &amp; Judy Sneddon <sneddon a="" c="" family=""> 125,000 Options – Exercise Price A\$0.40 &amp; Expiry Date 19 September 2018  Indirect:  HSBC Custody Nominees (Australia) Limited as custodian for Andrew Sneddon &amp; Judith Sneddon ATF Sneddon Family Superannuation Fund – 611,111 Fully Paid</sneddon></aj>
	Ordinary Shares.
Class	Fully Paid Ordinary Shares
Number acquired	Nil
Number disposed	611,111
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$0.045

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	<u>Direct:</u>
	Andrew Sneddon:  1,000,000 Options – Exercise Price A\$0.45 Expiry Date of 5 November 2018  600,000 Options – Exercise Price A\$0.65 Expiry Date of 31 August 2018
	Andrew Sneddon <aj family="" sneddon="" trust="">: 364,893 Fully Paid Ordinary Shares</aj>
	Andrew Sneddon & Judy Sneddon < Sneddon Family A/C> 125,000 Options – Exercise Price A\$0.40 & Expiry Date 19 September 2018
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	On-market trade.

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - +Closed period

Were the interests in the securities or contracts	No
detailed above traded during a +closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

29 June 2017

Appendix 3Y Page 4 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.